comparemela.com
Home
Live Updates
Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers. : comparemela.com
Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.
/PRNewswire/ -- Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation1 led by researchers at The...
Related Keywords
United States ,
Texas ,
American ,
Greenfire Bio ,
Zhen Lu ,
Robert Bast ,
Steve Morris ,
Bajit Gill ,
World Cancer Research Fund International ,
Linkedin ,
University Of Texas Md Anderson Cancer Center ,
Facebook ,
American Cancer Society ,
Cancer Center ,
Scientific Advisory Board ,
Clinical Investigation ,
American Cancer ,
World Cancer Research Fund ,
Clinical Study ,
Recurrent Ovarian ,
Primary Peritoneal ,
Fallopian Tube Cancers ,
Green3bio ,
comparemela.com © 2020. All Rights Reserved.